Views & Analysis
Gene editing: beyond the hype

Gene editing: beyond the hype

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.

Market Access
The State of The U.S. Biosimilar Market: Predictions for 2021

The US biosimilar market: Predictions for 2021

It has been five years since the first biosimilar launched in the United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D